ACADIA Pharmaceuticals Inc
NASDAQ:ACAD

Watchlist Manager
ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Watchlist
Price: 16.37 USD 1.17% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
ACADIA Pharmaceuticals Inc?
Write Note

Net Margin
ACADIA Pharmaceuticals Inc

13.8%
Current
-24%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
13.8%
=
Net Income
128.5m
/
Revenue
929.2m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
2.7B USD
14%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
9%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.6B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.8B EUR
-14%
Country US
Market Cap 2.7B USD
Net Margin
14%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 312.7B USD
Net Margin
9%
Country US
Market Cap 158.3B USD
Net Margin
13%
Country US
Market Cap 116.2B USD
Net Margin
-5%
Country US
Market Cap 112.4B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 133.6B AUD
Net Margin
18%
Country US
Market Cap 81.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.8B EUR
Net Margin
-14%
No Stocks Found

ACADIA Pharmaceuticals Inc
Glance View

Market Cap
2.7B USD
Industry
Biotechnology

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 514 full-time employees. The company went IPO on 2004-05-27. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The firm has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The firm also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

ACAD Intrinsic Value
19.77 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
13.8%
=
Net Income
128.5m
/
Revenue
929.2m
What is the Net Margin of ACADIA Pharmaceuticals Inc?

Based on ACADIA Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of 13.8%.